Contract award notice
Results of the procurement procedure
Section I: Contracting
authority
I.1) Name and addresses
Commercial Medicines Unit
2nd Floor, Rutland House
Runcorn
WA7 2ES
UK
E-mail: michelle.clarke6@nhs.net
NUTS: UK
Internet address(es)
Main address: https://cmu.bravosolution.co.uk
I.4) Type of the contracting authority
Ministry or any other national or federal authority, including their regional or local subdivisions
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
NHS Framework Agreement for branded pharmaceuticals — Midlands and East — Tranche B.
II.1.2) Main CPV code
33600000
II.1.3) Type of contract
Supplies
II.1.4) Short description
NHS Framework Agreement for Branded Pharmaceuticals for Midlands and East of England Tranche B
Offer reference number: CM/PHR/14/5448.
Period of framework agreement: 1.3.2017 to 28.2.2019 plus an option to extend for up to 24 months.
II.1.6) Information about lots
This contract is divided into lots:
Yes
II.1.7) Total value of the procurement
Value excluding VAT:
409 517 948.00
GBP
II.2) Description
Lot No: 1
II.2.1) Title
Midlands and East comprising West Midlands, East Midlands and East of England
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKH
UKF
UKG
II.2.4) Description of the procurement
Products associated with the lots are listed on Document No 06c of the Invitation to Offer. Each individual National Product Code (NPC) pack description in each of the regions (Midlands and East, West Midlands, East Midlands and East of England) is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector.
II.2.5) Award criteria
Quality criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 2
II.2.1) Title
West Midlands
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKG
II.2.4) Description of the procurement
Offer. Each individual National Product Code (NPC) pack description in each of the regions (Midlands and East, West Midlands, East Midlands and East of England) is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector.
II.2.5) Award criteria
Quality criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 3
II.2.1) Title
East Midlands
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKF
II.2.4) Description of the procurement
Offer. Each individual National Product Code (NPC) pack description in each of the regions (Midlands and East, West Midlands, East Midlands and East of England) is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above.
II.2.5) Award criteria
Quality criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Lot No: 4
II.2.1) Title
East of England
II.2.2) Additional CPV code(s)
33600000
II.2.3) Place of performance
NUTS code:
UKH
II.2.4) Description of the procurement
Offer. Each individual National Product Code (NPC) pack description in each of the regions (Midlands and East, West Midlands, East Midlands and East of England) is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for, or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may als..
II.2.5) Award criteria
Quality criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
Cost criterion: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document
/ Weighting: See over
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
Section V: Award of contract
A contract/lot is awarded:
Yes
V.2 Award of contract
V.2.1) Date of conclusion of the contract
13/02/2017
V.2.2) Information about tenders
Number of tenders received: 30
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
For details of the awarded supplier, please see section VI.2)
Runcorn
UK
NUTS: UK
The contractor is an SME:
No
V.2.4) Information on value of the contract/lot (excluding VAT)
Total value of the contract/lot:
: 409 517 948.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
Awarded suppliers -
Astellas Pharma Ltd;
AstraZeneca UK Ltd;
Aventis Pharma Ltd trading as Sanofi;
Basilea Pharmaceuticals Ltd;
Bayer Plc;
Biogen Ltd;
Bristol-Myers Squibb Pharmaceuticals Limited;
Daiichi Sankyo UK Ltd;
Eli Lilly and Company Ltd;
Ferring Pharmaceuticals Limited;
Finox Biotech;
Genzyme Therapeutics Ltd;
Gilead Sciences Ltd;
Ipsen Limited;
Janssen-Cilag Ltd;
LEO Pharma;
Merck Pharmaceuticals;
MSD;
Napp Pharmaceuticals Ltd;
Novartis Pharmaceuticals UK Ltd;
Novo Nordisk Ltd;
Pfizer Ltd;
Pharmasure Ltd;
Roche Products Ltd;
Takeda UK;
Teva UK Ltd;
UCB Pharma Ltd.
VI.4) Procedures for review
VI.4.1) Review body
Commercial Medicines Unit
Runcorn
UK
VI.5) Date of dispatch of this notice
21/04/2017